---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016457"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:35:34.751307+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics Q2 2022 net loss $28.4M; cash $180.9M; IND submissions on track

## Summary
- Net loss $28.4M ($0.69 per share); R&D expense $20.9M; G&A expense $7.7M.
- Cash, equivalents and marketable securities $180.9M; expected to fund operations into H2 2023.
- IND submissions for TN-201 (MYBPC3) and TN-301 (HDAC6) remain on track for H2 2022.
- Manufacturing facility in Union City launched, state-licensed for cGMP drug product at 1000L scale.
- Preclinical data presented on TN-401 (PKP2 gene therapy) and novel AAV capsids improving cardiac tropism.

## SEC filing metadata
- accession: 0000950170-22-016457
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017022016457/0000950170-22-016457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017022016457/tnya-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016457
- JSON: https://secwatch.observer/filing/0000950170-22-016457.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016457.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.